Although the body of research is growing, therapeutic efforts to curb or reverse hearing loss fall far short of those in the more prominent sensory impairment of vision loss. Several dozen drugs are approved to treat visual disorders such as macular degeneration and glaucoma that can lead to blindness. In contrast, not a single drug is approved to treat or prevent hearing loss. Read More
As we move towards the final quarter of the year, global biopharma companies have already raised an incredible $50 billion from public and private financing deals, which represents twice the amount raised for the whole of last year. The cash continues to flow particularly from public offerings. According to a report released by Renaissance Capital the U.S. IPO market as a whole is on track for its busiest year since 2014, with offerings predicted to come thick and fast post Labor Day. Read More
